规格 | 价格 | 库存 | 数量 |
---|---|---|---|
50mg |
|
||
100mg |
|
||
250mg |
|
||
500mg |
|
||
Other Sizes |
|
体外研究 (In Vitro) |
一个配体用于 E3 泛素连接酶,另一个配体用于靶蛋白;这两个配体通过接头连接形成 PROTAC。 PROTAC 利用细胞内泛素-蛋白酶体系统特异性破坏靶蛋白[1]。
|
---|---|
参考文献 |
[1]. Buckley DL, et al. HaloPROTACS: Use of Small Molecule PROTACs to Induce Degradation of HaloTag Fusion Proteins. ACS Chem Biol. 2015 Aug 21;10(8):1831-7.
|
分子式 |
C16H31CLO7
|
---|---|
分子量 |
370.866145372391
|
CAS号 |
1799506-30-1
|
SMILES |
ClCCCCCCOCCOCCOCCOCCOCC(O)=O
|
别名 |
PROTAC Linker 4
|
存储方式 |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
运输条件 |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
溶解度 (体外) |
Ethanol : ~100 mg/mL (~269.64 mM)
DMSO : ~100 mg/mL (~269.64 mM) |
---|
制备储备液 | 1 mg | 5 mg | 10 mg | |
1 mM | 2.6964 mL | 13.4818 mL | 26.9636 mL | |
5 mM | 0.5393 mL | 2.6964 mL | 5.3927 mL | |
10 mM | 0.2696 mL | 1.3482 mL | 2.6964 mL |
1、根据实验需要选择合适的溶剂配制储备液 (母液):对于大多数产品,InvivoChem推荐用DMSO配置母液 (比如:5、10、20mM或者10、20、50 mg/mL浓度),个别水溶性高的产品可直接溶于水。产品在DMSO 、水或其他溶剂中的具体溶解度详见上”溶解度 (体外)”部分;
2、如果您找不到您想要的溶解度信息,或者很难将产品溶解在溶液中,请联系我们;
3、建议使用下列计算器进行相关计算(摩尔浓度计算器、稀释计算器、分子量计算器、重组计算器等);
4、母液配好之后,将其分装到常规用量,并储存在-20°C或-80°C,尽量减少反复冻融循环。
计算结果:
工作液浓度: mg/mL;
DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL)。如该浓度超过该批次药物DMSO溶解度,请首先与我们联系。
体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL ddH2O,混匀澄清。
(1) 请确保溶液澄清之后,再加入下一种溶剂 (助溶剂) 。可利用涡旋、超声或水浴加热等方法助溶;
(2) 一定要按顺序加入溶剂 (助溶剂) 。
Schematic depiction of a bifunctional HaloPROTAC containing chloroalkane (which binds HaloTag7 fusion proteins) and a hydroxyproline derivative which binds VHL. A) The enantiomers of HaloPROTACs (containing D-amino acid residues) which do not bind VHL do not induce degradation of GFP-HaloTag7, supporting the necessity of VHL binding for activity. B) Pre-treatment with excessent-HaloPROTAC3 (1 hour) prevents degradation of GFP-HaloTag7 by HaloPROTAC3 after 24 hours. C) Pre-treatment with epoxomicin (4 hours) prevents degradation of GFP-HaloTag7 by HaloPROTAC3 after 20 hours. D)Treatment with VL285 attenuates the ability of HaloPROTAC3 to induce the degradation of GFP-HaloTag7. E) Structure of VL285. All error bars depict SEM.ACS Chem Biol.2015 Aug 21;10(8):1831-7. th> |
---|
The average fluorescence per cell compared to vehicle control was measured by flow cytometry after 24 hour treatment with the indicated compounds and concentrations. A) Comparison of HaloPROTAC3 (quintuplicate) to Hyt36 (triplicate) shows that HaloPROTAC3 is significantly more potent and efficacious. B) HaloPROTAC3 leads to 50% degradation of GFP-HaloTag7 within 4 to 8 hours. C) Significant recovery from 24 hour treatment with HaloPROTAC3 is observed after a 24 hour washout.ACS Chem Biol.2015 Aug 21;10(8):1831-7. td> |
A) A study of linker length with Degradation Inducing Moiety B shows that three ethylene glycol units are optimal for the degradation of GFP-HaloTag7. B) Structures of HaloPROTACs that have weaker affinity for VHL. C) Reducing the affinity for VHL attenuates their ability to induce degradation of GFP-HaloTag7, although the effect is not necessarily linear. Immunoblotting confirms that nearly complete degradation of A) GFP-HaloTag7 is observed after 24 hour treatment with 500 nM HaloPROTAC3, with significant degradation at 50 nM HaloPROTAC3. HaloPROTAC3 can lead to degradation of other HaloTag7 fusion proteins such as B) HaloTag7-ERK1 and HaloTag7-MEK1.ACS Chem Biol.2015 Aug 21;10(8):1831-7. td> |